FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average I	nurden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Viret Jean-Frederic</u>						2. Issuer Name and Ticker or Trading Symbol Coherus BioSciences, Inc. [CHRS]								heck al [l applio Directo	nship of Reporting applicable) Director Officer (give title		son(s) to Iss 10% O Other (s	ner
(Last) (First) (Middle) COHERUS BIOSCIENCES, INC. 333 TWIN DOLPHIN DRIVE, SUITE 600						3. Date of Earliest Transaction (Month/Day/Year) 09/26/2016									below) bel				specify
(Street) REDWC	OOD C.	A	94065			4. If Amendment, Date of Original Filed (Month/Day/Year)								ne) <mark>X</mark>	lividual or Joint/Group Fi Form filed by One R Form filed by More t Person			orting Perso	on
(City)	(S		(Zip)																
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/N			tion	n 2A. Deer Execution 'ear) if any			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5. Amount Securities Beneficiall Owned Fo		es For ally (D) Following (I) (n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	т		norted nsaction(s) etr. 3 and 4)			(Instr. 4)	
Common Stock, \$0.0001 par value 09/26			09/26/2	016	16			M		3,900	A	\$13.5	5 (5,225		D		
Common Stock, \$0.0001 par value 09/2			09/26/2	016)16					3,900	D	\$29.884	6 ⁽²⁾	2,	2,325		D		
		T	able I								posed of , converti			y Ow	ned				
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed tion Date, n/Day/Year)	Date, Transa				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owners Form: y Direct (or Indir (I) (Inst	Ownership	Beneficial Ownership ct (Instr. 4)
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to	\$13.5	09/26/2016			M			3,900	(3	3)	11/05/2024	Common	¹ 3,900	\$0	.00	128,748	3	D	

Explanation of Responses:

- 1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
- 2. The transaction was executed in multiple trades in prices ranging from \$29.59 to \$30.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- 3. The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from September 22, 2014 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Remarks:

buy)

/s/ Jean Frederic Viret 09/28/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.